MedTrace Logo

A Study to Assess the Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes

NCT00351507 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2012-05-07

No results posted yet for this study

Summary

This study was designed to directly assess the effects of vildagliptin on gastric emptying in people with type 2 diabetes.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Vildagliptin

Sponsors & Collaborators

Principal Investigators

  • Adrian Vella, MD · Mayo Clinic & Foundation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
35 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2006-02-28
Completion
2006-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00351507 on ClinicalTrials.gov